A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06836037
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
20 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Efinopegdutide — DRUG
    Subcutaneous injection
  • Placebo — DRUG
    placebo matching efinopegdutide

Study Details

The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.

Key Dates

Start date
Sep 5, 2022
Status verified
Feb 2025
Primary completion
Feb 2, 2023
Completion
Feb 2, 2023

Study Design

Enrollment
56 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Efinopegdutide Low Dose
    Participants receive low dose efinopegdutide at a single dose on day 1
  • Experimental: Efinopegdutide Medium dose
    Participants receive medium dose efinopegdutide at a single dose on day 1
  • Experimental: Efinopegdutide High Dose
    Participants receive high dose efinopegdutide at a single dose on day 1
  • Experimental: Efinopegdutide Multiple Dose
    Participants receive multiple doses of efinopegdutide over 78 days
  • Placebo Comparator: Placebo
    Participants receive placebo to match efinopegdutide dose and regimen

Primary Outcome Measure

Number of Participants Who Experience an Adverse Event (AE) [ Time Frame: Up to approximately 112 days ]

Related Studies